Are We Past the Checkpoint?

10:15 AM - 11:15 AM (EDT), Thursday, June 8, 2023 ・ Session Room 254A
More than 10 years ago, the first immune checkpoint inhibitor (ICI) was approved in a monumental moment for the field of oncology, leading to eight approved drugs against three targets (PD-1/PD-L1, CTLA-4 and LAG3). While there has been success, the field has faced disproportionate setbacks, most recently multiple high-profile Phase 3 failures. The question remains, what is the future of the ICI space? What are the up-and-coming approaches to reactivating the body's own immune system?

This discussion will explore how the field of immuno-oncology has evolved, strategies to improve success in ICIs, including combination therapies, and entirely new approaches aimed to be more targeted and with reduced side effects.
Moderator
Deputy Editor
Fierce Pharma
Speakers
President and CEO
Sonata therapeutics
Chief Executive Officer
Cue Biopharma
Chief Executive Officer, Chairman and Director
Portage Biotech